[1]钟 群,丁 娟,张 勇.依诺肝素钠联合低分子肝素钙治疗对重度子痫前期患者PIGF、sFlt-1水平的影响[J].医学信息,2024,37(22):122-125.[doi:10.3969/j.issn.1006-1959.2024.22.030]
　ZHONG Qun,DING Juan,ZHANG Yong.Effect of Enoxaparin Sodium Combined with Low Molecular Weight Heparin Calcium on PIGF and sFlt-1 Levels in Patients with Severe Preeclampsia[J].Journal of Medical Information,2024,37(22):122-125.[doi:10.3969/j.issn.1006-1959.2024.22.030]
点击复制

依诺肝素钠联合低分子肝素钙治疗对重度子痫前期患者PIGF、sFlt-1水平的影响()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年22期
页码:
122-125
栏目:
论著
出版日期:
2024-11-15

文章信息/Info

Title:
Effect of Enoxaparin Sodium Combined with Low Molecular Weight Heparin Calcium on PIGF and sFlt-1 Levels in Patients with Severe Preeclampsia
文章编号:
1006-1959（2024）22-0122-04
作者:
钟 群; 丁 娟; 张 勇
于都县人民医院药剂科，江西 于都 342300
Author(s):
ZHONG Qun; DING Juan; ZHANG Yong
Pharmacy Department of Yudu County People’s Hospital,Yudu 342300,Jiangxi,China
关键词:
依诺肝素钠; 低分子肝素钙; 重度子痫前期; PIGF; sFlt-1
Keywords:
Enoxaparin sodium; Low molecular weight heparin calcium; Severe preeclampsia; PIGF; sFlt-1
分类号:
R714.244；R587.1
DOI:
10.3969/j.issn.1006-1959.2024.22.030
摘要:
目的 研究依诺肝素钠联合低分子肝素钙治疗对重度子痫前期患者胎盘生长因子（PIGF）、可溶性血管内皮生长因子受体1（sFlt-1）水平的影响。方法 选取2022年5月-2023年10月在我院诊治的62例重度子痫前期患者为研究对象，采用随机数字表法分为常规组（31例）和研究组（31例）。常规组以低分子肝素钙治疗，研究组以低分子肝素钙+依诺肝素钠治疗，比较两组治疗效果、凝血功能指标、PIGF、sFlt-1水平、产妇并发症发生率及胎儿不良结局。结果 研究组治疗总有效率（96.77%）高于常规组（80.65%）（P＜0.05）；两组治疗后APTT、PT大于治疗前，D-D、FIB小于治疗前，且研究组APTT、PT大于常规组，D-D、FIB小于常规组（P＜0.05）；两组治疗后PIGF高于治疗前，sFlt-1低于治疗前，且研究组PIGF高于常规组，sFlt-1低于常规组（P＜0.05）；研究组产妇并发症发生率（6.45%）低于常规组（19.35%）（P＜0.05）；研究组胎儿不良结局发生率（3.23%）低于常规组（16.13%）（P＜0.05）。结论 依诺肝素钠联合低分子肝素钙治疗重度子痫前期效果确切，可提高治疗效果和患者PIGF水平，降低sFlt-1水平，改善凝血功能，预防母体并发症，改善胎儿不良结局，对母婴具有积极的影响。
Abstract:
Objective To study the effect of enoxaparin sodium combined with low molecular weight heparin calcium on the levels of placental growth factor (PIGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) in patients with severe preeclampsia.Methods A total of 62 patients with severe preeclampsia diagnosed and treated in our hospital from May 2022 to October 2023 were selected as the research objects. They were divided into routine group and study group by random number table method, with 31 patients in each group. The routine group was treated with low molecular weight heparin calcium, and the study group was treated with low molecular weight heparin calcium+enoxaparin sodium. The therapeutic effect, coagulation function indexes [D-dimer (D-D), fibrinogen (FIB), activated partial thromboplastin time (APTT), prothrombin time (PT)], PIGF, sFlt-1 levels, incidence of maternal complications and fetal adverse outcomes were compared between the two groups.Results The total effective rate of treatment in the study group (96.77%) was higher than that in the routine group (80.65%) (P<0.05). After treatment, APTT and PT in the two groups were higher than those before treatment, D-D and FIB were lower than those before treatment, and APTT and PT in the study group were higher than those in the routine group, D-D and FIB were lower than those in the routine group (P<0.05). After treatment, PIGF in the two groups was higher than that before treatment, sFlt-1 was lower than that before treatment, and PIGF in the study group was higher than that in the routine group, sFlt-1 was lower than that in the routine group (P<0.05). The incidence of maternal complications in the study group (6.45%) was lower than that in the routine group (19.35%) (P<0.05). The incidence of fetal adverse outcomes in the study group (3.23%) was lower than that in the routine group (16.13%) (P<0.05).Conclusion Enoxaparin sodium combined with low molecular weight heparin calcium is effective in the treatment of severe preeclampsia. It can improve the therapeutic effect and PIGF level of patients, reduce the level of sFlt-1, improve coagulation function, prevent maternal complications, improve fetal adverse outcomes, and have a positive impact on mothers and infants.

参考文献/References:

[1]刘学铭,淮瑞敏,吴玲娟,等.低分子肝素对重度子痫前期患者疗效及凝血功能的影响[J].中国社区医师,2021,37(9):35-36.[2]王丽,赵朵朵.硝苯地平和低分子肝素钙联合治疗对早发型重度子痫前期患者氧化应激,血压及母婴结局的影响[J].新乡医学院学报,2023,40(3):249-252.[3]韩贝贝.拉贝洛尔联合依诺肝素对重度子痫前期患者血压及血清学指标的影响[J].河南医学高等专科学校学报,2021,33(1):39-42.[4]Lecarpentier E,Gris JC,Cochery-Nouvellon E,et al.Angiogenic Factor Profiles in Pregnant Women With a History of Early-Onset Severe Preeclampsia Receiving Low-Molecular-Weight Heparin Prophylaxis[J].Obstet Gynecol,2018,131(1):63-69.[5]刘凤.重度子痫前期合并胎盘早剥的临床特征及其对母婴结局的影响[J].中国社区医师,2020,36(32):46-47.[6]何玉娥,余姗姗,林红,等.低分子肝素辅助治疗早发型重度子痫前期的临床效果[J].广西医学,2017,39(8):1132-1134,1138.[7]顾佳士,杨晓宁,戴海燕,等.子痫前期患者血清中PAPP-A 及VEGF与胎盘病理改变的相关性[J].检验医学与临床,2017,14(22):3335-3336,3339.[9]周伟宁,黄演林,钟志成,等.血清 sFlt-1/PLGF 比值与重度子痫前期的相关性及其预测价值研究[J].中国妇幼保健,2018,33(23):5394-5396.[10]杨勉,回广飞.妊娠早期血清可溶性血管内皮生长因子受体-1、促血管生成因子与子痫前期相关性研究[J].临床军医杂志,2019,47(7):700-701.[11]黄杏红,邵懿,罗正春.硫酸镁与硝苯地平联合丹参治疗对子痫前期患者胎盘血流灌注及氧化应激、细胞凋亡的影响[J].海南医学院学报,2017,23(10):1373-1376.[12]孙建华,王龙琼,漆洪波.低分子肝素钙对早发型重度子痫前期患者临床疗效与母体血清学指标及母婴结局的影响[J].西部医学,2018,30(11):1583-1588.[13]尚清,刑小芬,李军霞,等.低分子肝素钠与肝素钙辅助治疗对妊娠子痫前期患者肾功能及凝血功能的影响[J].贵州医药,2018,42(11):1305-1306.[14]张静,崔竞红,周文君,等.低分子肝素联合硫酸镁、拉贝洛尔治疗早发型重度子痫前期患者对妊娠结局的影响分析[J].现代诊断与治疗,2019,30(1):16-18.[15]郭莉,田小娟,杨志伟.硫酸镁联合硝苯地平对子痫前期患者血清同型半胱氨酸、胎盘生长因子及妊娠的影响[J].宁夏医科大学学报,2018,40(8):919-923.[16]栾燕东,王晓伟,赵巧棉,等.低分子肝素钙对早发型重度子痫前期患者后血清sFlt-1及PAPP-A表达水平影响[J].河北医学,2023,29(12):2097-2101.[17]许丽丽,王芳,文清,等.依诺肝素钠与低分子肝素钠治疗重度子痫前期的疗效及对血清LPO、Cys C和PIGF影响的对比研究 [J].中国医院用药评价与分析,2021,21(8):925-928.[18]崔誉文,霍健.复方丹参注射液联合低分子肝素对早发型重度子痫前期疗效及安全性研究[J].世界中西医结合杂志,2017,12(8):1148-1151.[19]刘伟,赵丹,刘倩,等.维生素E低相对分子质量肝素联合硫酸镁对早发型重度子痫前期患者核因子κB正五聚蛋白3水平及围生结局的影响[J].山西医药杂志,2018,47(23):2797-2799.[20]徐静.依诺肝素钠联合硫酸镁治疗重度子痫前期的效果[J].河南医学研究,2020,29(28)：5305-5307.

相似文献/References:

[1]邹万芹,孙立军.地屈孕酮联合低分子肝素钙治疗先兆流产患者的效果[J].医学信息,2019,32(14):151.[doi:10.3969/j.issn.1006-1959.2019.14.050]
　ZOU Wan-qin,SUN Li-jun.Effect of Dydrogesterone Combined with Low Molecular Weight Heparin Calcium in Patients with Threatened Abortion[J].Journal of Medical Information,2019,32(22):151.[doi:10.3969/j.issn.1006-1959.2019.14.050]
[2]贾科锋,魏召劝,郭亚堂,等.阿哌沙班与低分子肝素钠在膝关节置换术后抗凝治疗的对比[J].医学信息,2022,35(15):55.[doi:10.3969/j.issn.1006-1959.2022.15.011]
　JIA Ke-feng,WEI Zhao-quan,GUO Ya-tang,et al.Comparison of Anticoagulant Therapy Between Apixaban and Low Molecular Heparin Sodium After Knee Arthroplasty[J].Journal of Medical Information,2022,35(22):55.[doi:10.3969/j.issn.1006-1959.2022.15.011]
[3]张丽娜,张胜英.低分子肝素钙预防高危产妇剖宫产术后下肢静脉血栓的临床观察[J].医学信息,2019,32(21):95.[doi:10.3969/j.issn.1006-1959.2019.21.029]
　ZHANG Li-na,ZHANG Sheng-ying.Clinical Observation of Low Molecular Weight Heparin Calcium in Prevention of Lower Extremity Venous Thrombosis after High-Risk Maternal Cesarean Section[J].Journal of Medical Information,2019,32(22):95.[doi:10.3969/j.issn.1006-1959.2019.21.029]
[4]蔡庆宇,刘海洲.利伐沙班和低分子肝素钙预防中重度脑出血术后下肢深静脉血栓形成的效果比较[J].医学信息,2021,34(08):150.[doi:10.3969/j.issn.1006-1959.2021.08.040]
　CAI Qing-yu,LIU Hai-zhou.Comparison of the Effects of Rivaroxaban and Low-molecular-weight Heparin Calcium in Preventing Deep Vein Thrombosis of Lower Extremities After Moderate to Severe Intracerebral Hemorrhage[J].Journal of Medical Information,2021,34(22):150.[doi:10.3969/j.issn.1006-1959.2021.08.040]

更新日期/Last Update: 1900-01-01